<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979638</url>
  </required_header>
  <id_info>
    <org_study_id>BUS-P2-01</org_study_id>
    <secondary_id>2019-000375-16</secondary_id>
    <nct_id>NCT03979638</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Health Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Health Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose&#xD;
      escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have two 16-day treatment periods (four escalating doses or matching placebo&#xD;
      at four days interval) separated by a 10 to 14-day washout period. There will be a 14-day&#xD;
      follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial was terminated due to the impact of the COVID-19 on trial activities. 68 patients with&#xD;
    refractory chronic cough were enrolled with 52 completing treatment&#xD;
  </why_stopped>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">April 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two-arm, Two-Period, crossover assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Awake Objective Cough Frequency on Log-transformed Scale</measure>
    <time_frame>Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses</time_frame>
    <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency &gt; or = 20 Coughs/Hour at Baseline</measure>
    <time_frame>Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses</time_frame>
    <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency &gt; or = 20 coughs/hour at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency &gt; or = Median (32.4 Coughs/Hour) at Baseline</measure>
    <time_frame>Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12,16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses</time_frame>
    <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency &gt; or = median (32.4 coughs/hour) at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Chronic Refractory Cough</condition>
  <arm_group>
    <arm_group_label>BLU-5937 oral tablet BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral tablet BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized crossover design of matching placebo tablets to be administered orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLU-5937</intervention_name>
    <description>Four escalating doses of BLU-5937 administered BID over the course of the study</description>
    <arm_group_label>BLU-5937 oral tablet BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for BLU-5937</description>
    <arm_group_label>Placebo oral tablet BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unexplained or refractory chronic cough for at least one year&#xD;
&#xD;
          -  Chest radiograph or CT thorax within the last 60 months not demonstrating any&#xD;
             abnormality considered to be significantly contributing to the chronic cough&#xD;
&#xD;
          -  Cough count of ≥ 10 per hour (Awake Cough Count) at Screening&#xD;
&#xD;
          -  Score of ≥ 40mm on the Cough Severity VAS at Screening&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative serum pregnancy test at&#xD;
             Screening&#xD;
&#xD;
          -  Women of child-bearing potential must use a highly effective contraception method from&#xD;
             Screening through the Follow-Up Visit&#xD;
&#xD;
          -  Male subjects and their partners of child-bearing potential must use 2 methods of&#xD;
             acceptable birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current smoker or individuals who have given up smoking within the past 6 months, or&#xD;
             those with &gt;20 pack-year smoking history&#xD;
&#xD;
          -  Diagnosis of COPD, bronchiectasis, idiopathic pulmonary fibrosis&#xD;
&#xD;
          -  Treatment with an ACE-inhibitor as the potential cause of a subject's cough, or&#xD;
             requiring treatment with an ACE-inhibitor during the study, or within 12 weeks prior&#xD;
             to the Screening Visit&#xD;
&#xD;
          -  FEV1/FVC &lt; 60%&#xD;
&#xD;
          -  History of upper respiratory tract infection or recent significant change in pulmonary&#xD;
             status within 4 weeks of the Baseline Visit&#xD;
&#xD;
          -  History of concurrent malignancy or recurrence of malignancy within 2 years prior to&#xD;
             Screening&#xD;
&#xD;
          -  History of a diagnosis of drug or alcohol dependency or abuse within the last 3 years&#xD;
&#xD;
          -  Clinically significant abnormal electrocardiogram (ECG) or laboratory tests at&#xD;
             Screening&#xD;
&#xD;
          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with trial participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             trial results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacky Smith, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy Associates Medical Group Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Santa Clara Valley</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Cough</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33778</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy &amp; Asthma Research</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Sinus Center</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Phillip Hospital</name>
      <address>
        <city>Llanelli</city>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Clinical Research Facility</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <results_first_submitted>July 5, 2021</results_first_submitted>
  <results_first_submitted_qc>July 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2021</results_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unexplained or refractory chronic cough, P2X3 antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03979638/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 16 clinical trial sites in the United-Kingdom and in United States.</recruitment_details>
      <pre_assignment_details>A total of 68 participants were randomized to receive the study drug (BLU-5937) followed by placebo (33 participants) or placebo followed by the study drug (35 participants).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BLU-5937 &gt; Placebo</title>
          <description>Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID&#xD;
BLU-5937: Four escalating doses of BLU-5937 administered BID over the course of the study followed by matching Placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo &gt; BLU-5937</title>
          <description>Randomized crossover design of matching placebo tablets to be administered orally BID&#xD;
Placebo: Matching placebo for BLU-5937 follow by four escalating doses of BLU-5937</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population consisted of all randomized participants who have received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>BLU-5937 &gt; Placebo</title>
          <description>Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID&#xD;
BLU-5937: Four escalating doses of BLU-5937 administered BID over the course of the study followed by matching Placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo &gt; BLU-5937</title>
          <description>Randomized crossover design of matching placebo tablets to be administered orally BID&#xD;
Placebo: Matching placebo for BLU-5937 followed by four escalating doses of BLU-5937</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="11.49"/>
                    <measurement group_id="B2" value="63.7" spread="9.70"/>
                    <measurement group_id="B3" value="64.0" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Awake Objective Cough Frequency on Log-transformed Scale</title>
        <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
        <time_frame>Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses</time_frame>
        <population>Analysis population consisted of all randomized subjects who took at least one dose of study drug and provided at least one baseline and at least one post-baseline cough frequency measurement</population>
        <group_list>
          <group group_id="O1">
            <title>BLU-5937 - 25 mg</title>
            <description>BLU-5937 25 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator - 25 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O3">
            <title>BLU-5937 - 50 mg</title>
            <description>BLU-5937 50 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator - 50 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O5">
            <title>BLU-5937 - 100 mg</title>
            <description>BLU-5937 100 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo Comparator - 100 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O7">
            <title>BLU-5937 - 200 mg</title>
            <description>BLU-5937 200 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo Comparator - 200 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Awake Objective Cough Frequency on Log-transformed Scale</title>
          <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
          <population>Analysis population consisted of all randomized subjects who took at least one dose of study drug and provided at least one baseline and at least one post-baseline cough frequency measurement</population>
          <units>Log coughs/hour</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="58"/>
                <count group_id="O7" value="58"/>
                <count group_id="O8" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" lower_limit="-0.29" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.19" upper_limit="0.05"/>
                    <measurement group_id="O3" value="-0.20" lower_limit="-0.32" upper_limit="-0.08"/>
                    <measurement group_id="O4" value="-0.14" lower_limit="-0.26" upper_limit="-0.01"/>
                    <measurement group_id="O5" value="-0.25" lower_limit="-0.40" upper_limit="-0.09"/>
                    <measurement group_id="O6" value="-0.17" lower_limit="-0.30" upper_limit="-0.04"/>
                    <measurement group_id="O7" value="-0.33" lower_limit="-0.49" upper_limit="-0.17"/>
                    <measurement group_id="O8" value="-0.14" lower_limit="-0.29" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1424</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.5</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4602</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.8</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4181</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-7.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.4</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0855</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-16.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.3</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency &gt; or = 20 Coughs/Hour at Baseline</title>
        <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency &gt; or = 20 coughs/hour at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
        <time_frame>Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BLU-5937 - 25 mg</title>
            <description>BLU-5937 25 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator - 25 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O3">
            <title>BLU-5937 - 50 mg</title>
            <description>BLU-5937 50 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator - 50 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O5">
            <title>BLU-5937 - 100 mg</title>
            <description>BLU-5937 100 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo Comparator - 100 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O7">
            <title>BLU-5937 - 200 mg</title>
            <description>BLU-5937 200 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo Comparator - 200 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency &gt; or = 20 Coughs/Hour at Baseline</title>
          <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency &gt; or = 20 coughs/hour at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
          <units>Log coughs/hour</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" lower_limit="-0.34" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.09" upper_limit="0.10"/>
                    <measurement group_id="O3" value="-0.29" lower_limit="-0.42" upper_limit="-0.15"/>
                    <measurement group_id="O4" value="-0.09" lower_limit="-0.21" upper_limit="0.03"/>
                    <measurement group_id="O5" value="-0.33" lower_limit="-0.51" upper_limit="-0.16"/>
                    <measurement group_id="O6" value="-0.12" lower_limit="-0.25" upper_limit="0.01"/>
                    <measurement group_id="O7" value="-0.41" lower_limit="-0.58" upper_limit="-0.24"/>
                    <measurement group_id="O8" value="-0.09" lower_limit="-0.23" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-20.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.9</ci_lower_limit>
            <ci_upper_limit>-9.5</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0186</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.9</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0320</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-19.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.9</ci_lower_limit>
            <ci_upper_limit>-1.9</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-27.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.3</ci_lower_limit>
            <ci_upper_limit>-10.8</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency &gt; or = Median (32.4 Coughs/Hour) at Baseline</title>
        <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency &gt; or = median (32.4 coughs/hour) at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
        <time_frame>Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12,16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BLU-5937 - 25 mg</title>
            <description>BLU-5937 25 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator - 25 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O3">
            <title>BLU-5937 - 50 mg</title>
            <description>BLU-5937 50 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator - 50 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O5">
            <title>BLU-5937 - 100 mg</title>
            <description>BLU-5937 100 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O6">
            <title>Placebo Comparator - 100 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
          <group group_id="O7">
            <title>BLU-5937 - 200 mg</title>
            <description>BLU-5937 200 mg tablet administered orally BID for 4 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo Comparator - 200 mg</title>
            <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency &gt; or = Median (32.4 Coughs/Hour) at Baseline</title>
          <description>Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency &gt; or = median (32.4 coughs/hour) at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected</description>
          <units>Log coughs/hour</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" lower_limit="-0.45" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.11" upper_limit="0.15"/>
                    <measurement group_id="O3" value="-0.42" lower_limit="-0.55" upper_limit="-0.28"/>
                    <measurement group_id="O4" value="-0.08" lower_limit="-0.22" upper_limit="0.05"/>
                    <measurement group_id="O5" value="-0.44" lower_limit="-0.60" upper_limit="-0.27"/>
                    <measurement group_id="O6" value="-0.09" lower_limit="-0.24" upper_limit="0.06"/>
                    <measurement group_id="O7" value="-0.49" lower_limit="-0.68" upper_limit="-0.31"/>
                    <measurement group_id="O8" value="-0.10" lower_limit="-0.24" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-28.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.5</ci_lower_limit>
            <ci_upper_limit>-14.5</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-28.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.7</ci_lower_limit>
            <ci_upper_limit>-15.0</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-29.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.7</ci_lower_limit>
            <ci_upper_limit>-13.2</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Intention To Treat (ITT), statistical analysis follows a Mixed Model which uses log-transformation</method_desc>
            <param_type>Estimated percent change</param_type>
            <param_value>-32.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.3</ci_lower_limit>
            <ci_upper_limit>-16.4</ci_upper_limit>
            <estimate_desc>Percent change difference between BLU-5937 and placebo was estimated by 100 x [e^diff - 1] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality and Adverse Event data collection is up to 11 weeks</time_frame>
      <desc>Analysis population consisted of all randomized participants who received at least 1 dose of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>BLU-5937 - 25 mg</title>
          <description>BLU-5937 25 mg tablet administered orally BID for 4 days</description>
        </group>
        <group group_id="E2">
          <title>BLU-5937 - 50 mg</title>
          <description>BLU-5937 50 mg tablet administered orally BID for 4 days</description>
        </group>
        <group group_id="E3">
          <title>BLU-5937 - 100 mg</title>
          <description>BLU-5937 100 mg tablet administered orally BID for 4 days</description>
        </group>
        <group group_id="E4">
          <title>BLU-5937 - 200 mg</title>
          <description>BLU-5937 200 mg tablet administered orally BID for 4 days</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Matching Placebo for BLU-5937 administered orally BID for 4 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>colorectal cancer</sub_title>
                <description>colorectal cancer considered as not related to study drug was reported approximately 6 months after the last dose of study medication.</description>
                <counts group_id="E1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_at_risk="58"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No data collected as part of this study will be utilized in any written work, including publications, without the written consent of sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director Clinical Development</name_or_title>
      <organization>Bellus Health Inc</organization>
      <phone>833-703-0708</phone>
      <email>lharvey@bellushealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

